Zobrazeno 1 - 10
of 465
pro vyhledávání: '"MOTOTSUGU SHIMOKAWA"'
Autor:
Kaname Miyashita, Seijiro Shioi, Tatsuhiro Kajitani, Yumiko Koi, Mototsugu Shimokawa, Akitaka Makiyama, Shinya Oda, Taito Esaki
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Microsatellite instability (MSI) is now widely used as an indispensable biomarker. However, the relationship between MSI-H (high) and defective DNA mismatch repair (MMR) is not as straightforward as has been expected. Genome-edited cells car
Externí odkaz:
https://doaj.org/article/0cfc9a4391194efab3c41befb1974e3c
Autor:
Taro Shibuki, Taiga Otsuka, Mototsugu Shimokawa, Junichi Nakazawa, Shiho Arima, Masaru Fukahori, Keisuke Miwa, Yoshinobu Okabe, Futa Koga, Yujiro Ueda, Yoshihito Kubotsu, Akitaka Makiyama, Hozumi Shimokawa, Shigeyuki Takeshita, Kazuo Nishikawa, Azusa Komori, Satoshi Otsu, Ayumu Hosokawa, Tatsunori Sakai, Hisanobu Oda, Machiko Kawahira, Shuji Arita, Takuya Honda, Hiroki Taguchi, Kengo Tsuneyoshi, Yasunori Kawaguchi, Toshihiro Fujita, Takahiro Sakae, Kenta Nio, Yasushi Ide, Norio Ureshino, Tsuyoshi Shirakawa, Toshihiko Mizuta, Kenji Mitsugi
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract This study aimed to compare second-line treatment outcomes for patients with unresectable pancreatic cancer previously treated with gemcitabine plus nab–paclitaxel (GnP) therapy. We conducted an integrated analysis of two retrospective stu
Externí odkaz:
https://doaj.org/article/e7f02c7dbce94342bdbac0633ca1ffca
Autor:
Kyoto Matsudo, Shinkichi Takamori, Tomoyoshi Takenaka, Mototsugu Shimokawa, Asato Hashinokuchi, Taichi Nagano, Fumihiko Kinoshita, Takaki Akamine, Mikihiro Kohno, Gouji Toyokawa, Tomoharu Yoshizumi
Publikováno v:
Transplant International, Vol 37 (2024)
Bronchiolitis obliterans syndrome (BOS) is a chronic complication following lung transplantation that limits the long-term survival. Although the enhancer of zeste homolog 2 (EZH2) is involved in post-transplantation rejection, its involvement in BOS
Externí odkaz:
https://doaj.org/article/dce38c74c0ee4660b3f58facc7fa95e4
Autor:
Tomoko Kodama, Takashi Imajima, Mototsugu Shimokawa, Taiga Otsuka, Masahiro Kawahira, Junichi Nakazawa, Takeshi Hori, Taro Shibuki, Shiho Arima, Akio Ido, Keisuke Miwa, Yoshinobu Okabe, Futa Koga, Yujiro Ueda, Yoshihito Kubotsu, Hozumi Shimokawa, Shigeyuki Takeshita, Kazuo Nishikawa, Azusa Komori, Satoshi Otsu, Ayumu Hosokawa, Tatsunori Sakai, Kenji Sakai, Hisanobu Oda, Machiko Kawahira, Shuji Arita, Takuya Honda, Hiroki Taguchi, Kengo Tsuneyoshi, Yasunori Kawaguchi, Toshihiro Fujita, Takahiro Sakae, Tsuyoshi Shirakawa, Toshihiko Mizuta, Kenji Mitsugi
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Nanoliposomal irinotecan with fluorouracil and folinic acid (NFF) is a standard regimen after gemcitabine-based therapy for patients with unresectable or recurrent pancreatic cancer. However, there are limited clinical data on its efficacy a
Externí odkaz:
https://doaj.org/article/eebc9af936314345b048057f5416b5fd
Autor:
Yu Miyashita, Eiji Oki, Tomohiro Kamori, Yoshito Akagi, Shinichiro Mori, Norifumi Hattori, Kazuma Kobayashi, Mototsugu Shimokawa, Yoshinao Oda, Masaki Mori
Publikováno v:
Annals of Gastroenterological Surgery, Vol 8, Iss 2, Pp 251-261 (2024)
Abstract Aim Immune checkpoint inhibitors (ICIs) are less effective in mismatch repair (MMR)‐proficient (pMMR) colorectal cancers (CRCs) than in MMR‐deficient CRCs. Here, we investigated changes in the tumor microenvironment after neoadjuvant che
Externí odkaz:
https://doaj.org/article/bc63aa20c2804c5f90fb8853c1918850
Autor:
Hiroyuki Arai, Takashi Tsuda, Yu Sunakawa, Mototsugu Shimokawa, Kohei Akiyoshi, Shinya Tokunaga, Hirokazu Shoji, Kenji Kunieda, Masahito Kotaka, Toshihiko Matsumoto, Yusuke Nagata, Takuro Mizukami, Fumitaka Mizuki, Kathleen D. Danenberg, Narikazu Boku, Takako Eguchi Nakajima
Publikováno v:
Cancer Medicine, Vol 13, Iss 7, Pp n/a-n/a (2024)
Abstract Background Long‐term anti‐EGFR antibody treatment increases the risk of severe dermatologic toxicities. This single‐arm, phase II trial aimed to investigate the strategy of switching from cetuximab to bevacizumab in combination with FO
Externí odkaz:
https://doaj.org/article/f1dd28fe734a4a8888bd792971f6399b
Autor:
Masaru Fukahori, Yoshinobu Okabe, Mototsugu Shimokawa, Taiga Otsuka, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Tomoyuki Ushijima, Keisuke Miwa, Taro Shibuki, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Kenji Mitsugi, Tsuyoshi Shirakawa
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract First-line chemotherapy for patients with metastatic pancreatic cancer (MPC) includes gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX (FFX). However, the efficacy of second-line chemotherapy and the role of combination chemotherapy in c
Externí odkaz:
https://doaj.org/article/f5f37084f80443099bd5a4c15daea257
Autor:
Yuka Oku, Gouji Toyokawa, Sho Wakasu, Fumihiko Kinoshita, Shinkichi Takamori, Kenji Watanabe, Naoki Haratake, Taichi Nagano, Keisuke Kosai, Kazuki Takada, Airi Fujimoto, Kodo Higashijima, Yoshimasa Shiraishi, Kentaro Tanaka, Hiroaki Takeoka, Masaki Okamoto, Takanori Yamashita, Mototsugu Shimokawa, Fumihiro Shoji, Koji Yamazaki, Tatsuro Okamoto, Takashi Seto, Hitoshi Ueda, Sadanori Takeo, Naoki Nakashima, Isamu Okamoto, Tomoyoshi Takenaka, Tomoharu Yoshizumi
Publikováno v:
Cancer Medicine, Vol 12, Iss 13, Pp 14327-14336 (2023)
Abstract Background Immunotherapy has become a standard‐of‐care for patients with non‐small‐cell lung cancer (NSCLC). Although several biomarkers, such as programmed cell death‐1, have been shown to be useful in selecting patients likely to
Externí odkaz:
https://doaj.org/article/dd568051ef63481493a1e9c73bb90058
Autor:
Fumihiko Kinoshita, Mototsugu Shimokawa, Tomoyoshi Takenaka, Tatsuro Okamoto, Kenichi Taguchi, Yoshinao Oda, Tomoharu Yoshizumi
Publikováno v:
Thoracic Cancer, Vol 14, Iss 18, Pp 1651-1659 (2023)
Abstract Main Problems In non‐small‐cell lung cancer, ground‐glass opacity on computed tomography imaging reflects pathological noninvasiveness and is a favorable prognostic factor. However, the significance of pathological noninvasive areas (N
Externí odkaz:
https://doaj.org/article/d9b150b9d96d4064bfd791e94070faa0
Autor:
Tomoyoshi Takenaka, Tokujiro Yano, Koji Yamazaki, Tatsuro Okamoto, Motoharu Hamatake, Shinkichi Takamori, Mikihiro Kohno, Naoko Miura, Mototsugu Shimokawa, Tomoharu Yoshizumi, Kyushu University Lung Surgery Study Group
Publikováno v:
Thoracic Cancer, Vol 14, Iss 18, Pp 1660-1667 (2023)
Abstract Background Long‐term survival can be achieved with radical local therapy in some cases of postoperative recurrence of non‐small cell lung cancer (NSCLC). Here, we evaluated post‐recurrence survival (PRS) after treatment of postoperativ
Externí odkaz:
https://doaj.org/article/98abdd6d760c45e39f49da1c1de77da1